Abstract
Side effects of checkpoint inhibitor immunotherapy usually occur relatively early in the treatment. They most often start within the first few months after the start of therapy.
However, the first onset of these events was documented one year after the end of treatment. Differences in the time of onset and degree of intensity of these side effects are determined by the drug used, the particular treatment regimen and the actual immune system of the cancer patient in all its aspects.
Most side effects are standardly managed with corticosteroids. Corticoresistant forms of autoimmune inflammation require biological treatment based on neutralization of proinflammatory cytokines or other deeper forms of immunosuppression.
A more detailed knowledge of the pathophysiology of these side effects in our cancer patients will certainly help us to further refine and better target or prevent anti-inflammatory immunomodulatory therapy.